Tarsus PharmaceuticalsvsUnitedHealth

TARS and UNH stock compared: price, dividend, valuation and results, from SEC filings.

TARS

Tarsus Pharmaceuticals, Inc.

$78.20

Value $3.9B

-0.61%
TARS's page

UNH

UnitedHealth Group Incorporated

$389.68

Value $354B

-5.42%
UNH's page

Tarsus Pharmaceuticals (TARS) has a market value of $3.9B and UnitedHealth (UNH) $354B. Over the last year, with dividends, TARS moved +7.2% and UNH +24.3%. Dividend yield: TARS none, UNH 2.32%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    TARS$3.9B

    UNH$354B

    UNH is 92 times TARS

  • Revenue, 12 months

    TARS$682M

    UNH$450B

    UNH is 659 times TARS

  • Net income, 12 months

    TARS-$702M

    UNH$15.9B

  • Operating margin

    TARS-102.0%

    UNH5.3%

    107.3 points apart

  • ROIC

    TARS-149.3%

    UNH11.3%

    160.6 points apart

  • P/E

    TARS–

    UNH22.3

  • Dividend yield

    TARS0.0%

    UNH2.3%

    2.3 points apart

  • 5-year return

    TARS+194.5%

    UNH-5.1%

    199.6 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

TARS+194.5%

UNH-5.1%

10020030020222023202420252026
Returns by period
PeriodTARSWith dividendsUNHWith dividends
1 year since November 14, 2025+7.2%Price +7.2%+24.3%Price +21.1%
3 years since November 17, 2023+314.6%+60.7% a yearPrice +314.6%-22.6%-8.2% a yearPrice -27.3%
5 years since November 16, 2021+194.5%+24.1% a yearPrice +194.5%-5.1%-1.0% a yearPrice -13.3%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

TARSTarsus PharmaceuticalsUNHUnitedHealth

Valuation

TARSUNH
Valuation
Price$78.20$389.68
Market value$3.9B$354B
Enterprise value (EV)–$399B
P/E–22.3
P/E, 5-year median–25.0
P/B37.13.4
EV/EBIT–16.7
Free cash flow yield0.8%6.5%

Results and growth

TARSUNH
Results and growth
Revenue, 12 months$682M$450B
Net income, 12 months-$702M$15.9B
Free cash flow, 12 months$32M$22.8B
Earnings per share, 12 months-$15.18$17.52
Revenue growth, year on year146.7%11.8%
Revenue growth a year, past–+11.7%over 5 years
EPS growth a year, past–-3.8%over 5 years

Margins and returns on capital

TARSUNH
Margins and returns on capital
Gross margin–88.3%
Operating margin-102.0%5.3%
Net margin-102.9%3.5%
ROIC-149.3%11.3%
ROE-237.5%15.5%

Balance sheet

TARSUNH
Balance sheet
Cash$310M$28.5B
Total debt–$74.3B
Net debt / EBITDA–1.6
Interest cover-80.2×6.2×

Dividends and buybacks

TARSUNH
Dividends and buybacks
Dividend yield–2.3%
Dividend per share, 12 months–$9.06
Dividend growth a year, past–+12.6%over 5 years
Buyback yield–1.6%
Shareholder yield–3.9%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: TARS or UNH

Didn't find what you were looking for?

Ask us
Which is bigger, Tarsus Pharmaceuticals or UnitedHealth?

By market value, UnitedHealth ($354B) is about 91.7 times Tarsus Pharmaceuticals ($3.9B), at today's prices.

How did TARS and UNH stock do over the last 5 years?

Since November 16, 2021, TARS's price moved +194.5% and UNH's -13.3%. With dividends: TARS +194.5% (+24.1% a year), UNH -5.1% (-1.0% a year). Past returns do not predict future ones.

Which pays the higher dividend, TARS or UNH?

The dividend yield at today's price is none for Tarsus Pharmaceuticals and 2.32% for UnitedHealth. Over the last twelve months they paid – and $9.06 per share.

Which has the higher profit margins, Tarsus Pharmaceuticals or UnitedHealth?

Over the last twelve months, the net margin was -102.9% for Tarsus Pharmaceuticals and 3.5% for UnitedHealth, and the operating margin -102.0% and 5.3%. Revenue was $682M and $450B.

Which is the better investment, Tarsus Pharmaceuticals or UnitedHealth?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.